2/6/12

Radius Health, a biotech focused on the treatment of osteoporosis, registered with the SEC on Monday for an $86 million US IPO. The Cambridge, MA-based company has a Phase 3 product candidate that has the potential to restore bone density through daily injections. A patch form of the drug is in Phase 2 trials. Radius Health plans to list on the NASDAQ under the symbol RDUS. UBS and Leerink Swann are the lead underwriters on the deal.

Five biotechs have set terms this year. Verastem (VSTM) and Cempra (CEMP) are trading up 10% and 3%. Two more, ChemoCentryx (CCXI) and TVAX Biomedical (TVAX) are set to price this week. The fifth, Merrimack Pharmaceuticals (MACK), postponed its deal last Wednesday.